Notícias e Atividades da BlueRock Therapeutics

A BlueRock Therapeutics pertence à Bayer.

Bayer é uma das ...

• Dax 40;
• Forbes Global 2000 (#589);
• Fortune 500 Europe (#69);
• Global Fortune 500 (#301);
• Stoxx 600;
• TOB Iconic 10,000.

Bayer é uma empresa listada sob o símbolo BAYN (DE).

Bayer tem presença direta em 20 países.

Bayer possui 40 subsidiárias incluindo AskBio, Bayer ANZ e Bayer APAC.

Eles estão dentro:

• Farmacêutica68%
• Biotecnologia17%
• Outro15%

Fusão, aquisição e financiamento envolvendo Bayer.

• Bayer adquiriu Perfuse Therapeutics (publicado em 17 de junho de 2026).
• Bayer has announced the acquisition of Perfuse Therapeutics  (publicado em 6 de maio de 2026).

Veja o organograma con seus 38 executivos principais

Biografias mais buscadas da BlueRock Therapeutics

• Seth Ettenberg, Director, President and Chief Executive Officer
• Doug Kerr, Director
• Juergen Eckardt, Director

Recentes movimentos de executivos em BlueRock Therapeutics

• Stefan Irion, Chief Scientific Officer, deixou a Companhia  (Notícia publicada em 4 de maio de 2026).

Recentes movimentos de executivos em Bayer

• Alfred Stern, ingressou na Companhia como Director  (Notícia publicada em 9 de junho de 2026).
• Marcel Smits, ingressou na Companhia como Director  (Notícia publicada em 9 de junho de 2026).
• Thomas Matthias Meiers, ingressou na Companhia como Director  (Notícia publicada em 9 de junho de 2026).

Clique aqui para ver outras movimentos em Bayer

Criar um alerta
para seguir os movimentos de executivos da BlueRock Therapeutics.

Bayer possui 2.430 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).

Popular M&A news in Biotecnologia

• Tempus has announced the acquisition of Personalis  (publicado em 20 de julho de 2026).
• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Robert Gould - Board Member da Fulcrum Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de BlueRock Therapeutics

• News - BlueRock Therapeutics LP
• BlueRock Therapeutics Announces New Board Chair, New President and CEO - Engineered Cell TherapyBlueRock Therapeutics Announces New Board Chair, New President and CEO - Engineered Cell Therapy
• BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson's Disease - Engineered Cell TherapyBlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson's Diseas
• BlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson's Disease - Engineered Cell TherapyBlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced
• Senti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Therapies for Regenerative Medicine - Engineered Cell TherapySenti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Th
• BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases - Engineered Cell TherapyBlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis The
• BlueRock Therapeutics Receives Permission from Health Canada for DA01 Trial in Parkinson's Disease - Engineered Cell TherapyBlueRock Therapeutics Receives Permission from Health Canada for DA01 Trial in Parkinson's Disease - Engineered Cell Therapy
• BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson's Disease - Engineered Cell Therapy
• BlueRock Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa
• BlueRock Therapeutics President and CEO Emile Nuwaysir elected to serve as Vice Chairman of the Alliance for Regenerative Medicine
• View more press releases Close

Redes sociais sobre BlueRock Therapeutics

• BlueRock Therapeutics na Wikipedia, Google News e Yahoo Finance
• BlueRock Therapeutics na LinkedIn, X (Twitter) e YouTube